BJH - volume 11, issue Abstract Book BHS, february 2020
S. Snauwaert MD, PhD, T. Lodewyck MD, P. De Paepe MD, PhD
BJH - volume 8, issue 3, june 2017
T. Lodewyck MD
The 43rd annual meeting of the European Society for Blood and Marrow Transplantation took place in Marseille between March 26th and March 29th, 2017. The society celebrated 60 years of history in the field of hematopoietic stem cell transplantation. This report summarises some interesting abstracts that were presented during the meeting.
(BELG J HEMATOL 2017;8(3):122–4)
Read moreBJH - volume 5, issue 3, september 2014
T. Lodewyck MD
From 30 March – 2 April 2014, the annual meeting of the European Society for Blood and Marrow Transplantation was held in Milan, Italy. At this 40th anniversary meeting, the society celebrated 40 years of physicians meetings, 30 years of nurses meetings and introduced its first donor day. Some of the highlights of this meeting are summarised.
(BELG J HEMATOL 2014;5(3):113–14)
Read moreBJH - volume 5, issue Abstract Book BHS, january 2014
F. Nollet PhD, K. Boon , J. Emmerechts MD, PhD, S. Vermeire , R. D’Hondt , A. Van Hoof MD, PhD, D. Selleslag MD, J. Van Droogenbroeck MD, PhD, T. Lodewyck MD, J. Billiet MD
BJH - volume 3, issue 4, december 2012
S. Drieghe PharmD, B. Cauwelier MD, PhD, T. Lodewyck MD, D. Selleslag MD, J. Van Droogenbroeck MD, PhD, A. Van Hoof MD, PhD, J. Van Huysse MD, J. Billiet MD
Intravascular lymphoma is a rare haematological malignancy characterised by neoplastic proliferation of lymphoid cells particularly within the lumina of capillaries, heterogeneity in clinical presentation, disseminated disease with aggressive behaviour and often fatal course. In the present case report, we describe four cases of intravascular lymphoma diagnosed in a single centre over a period of ten years.
(BELG J HEMATOL 2012;3: 149–154)
Read moreBJH - volume 3, issue 3, september 2012
T. Lodewyck MD
From April 1 till 4 2012, the 38th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) was held in Geneva. The feld of stem cell transplantation keeps on growing, with more than 30,000 transplants being reported to the EBMT in 2010. Some of the highlights of this meeting are briefly summarised.
(BELG J HEMATOL 2012;3:109–111)
Read moreBJH - volume 3, issue 1, march 2012
T. Lodewyck MD
Clofarabine is a second-generation nucleoside analogue which has been rationally developed with the aim to combine the therapeutic qualities and avoid the toxic limitations of fludarabine and cladribine. Clofarabine has been reimbursed in Belgium for the treatment of paediatric patients up to the age of 21 years with relapsed or refractory Acute Lymphatic Leukaemia (ALL) after two or three preceding regimens respectively. Clinical efficacy has also been demonstrated in newly diagnosed and advanced Acute Myoblastic Leukaemia (AML). The drug is currently being investigated in several randomised trials in AML and ALL and as part of the conditioning regimen prior to stem cell transplantation. This article focuses on the pharmacology, toxicity and clinical efficacy of clofarabine.
(BELG J HEMATOL 2012;3:17–22)
Read more
Top
